Oppenheimer Reiterates Outperform on Zentalis Pharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating for Zentalis Pharma (NASDAQ:ZNTL) and maintained a $20 price target.
September 16, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating for Zentalis Pharma and maintained a $20 price target, indicating confidence in the company's potential.
The reiteration of an Outperform rating and maintenance of a $20 price target by a reputable analyst suggests positive sentiment and potential upside for Zentalis Pharma's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100